NY, NY—(7/24/2013) – Matthew Lehman, CEO of Prima BioMed, updated the financial community on the company’s recent progress during an exclusive interview with The Wall Street Analyst. He discussed the development of personalized immunocellular therapeutics, known as CVac, which uses the body’s own immune system to fight cancer. Mr. Lehman talked about the CANVAS trial in Germany, trends in the sector, and some of the factors that make the company unique. He also went over his background, experience, and goals for the upcoming year.
About The Wall Street Analyzer 1642 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.